RGEN:NASDAQ
Repligen Corp
$165.95
arrow_upward
+0.77%(+1.27) 1D
Sep 11, 10:48:42 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RGEN...
Open
$166.72
High
$168.06
Low
$164.02
Mkt. cap
9.37B
Avg. vol.
998.74K
Volume
179.90K
P/E ratio
226.20
52-wk high
$188.73
52-wk low
$100.99
EPS
$0.73
Beta
1.05
Shares outstanding
56.44M
No. of employees
2K
Open
$166.72
High
$168.06
Low
$164.02
Mkt. cap
9.37B
Avg. vol.
998.74K
Volume
179.90K
P/E ratio
226.20
52-wk high
$188.73
52-wk low
$100.99
EPS
$0.73
Beta
1.05
Shares outstanding
56.44M
No. of employees
2K
News stories
From web sources and news partners
Zacks
·
23 hours ago
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
TipRanks
·
1 day ago
BioLife Solutions Nears Completion of Repligen Acquisition
GuruFocus
·
1 day ago
RGEN Maintained by UBS -- Price Target Raised to $225
Profile
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN. Wikipedia
About Repligen Corp
CEOTony J. Hunt
Employees2K
Founded1981
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websiterepligen.com